Advertisement
PBYI vs RNAC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Buy and RNAC is a Buy.
PBYI's RSI Indicator leaves overbought zone
The 10-day RSI Indicator for PBYI moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 instances where the indicator moved out of the overbought zone. In 37 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a move down at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBYI as a result. In 76 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for PBYI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
PBYI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 261 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
PBYI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 210 of 231 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.640) is normal, around the industry mean (2.788). P/E Ratio (18.434) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (440.869).
Momentum Indicator for RNAC turns positive, indicating new upward trend
RNAC saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In 71 of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNAC's RSI Oscillator exited the oversold zone, 36 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for RNAC just turned positive on October 21, 2026. Looking at past instances where RNAC's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +7.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
RNAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 50 cases where RNAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for RNAC moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RNAC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.638) is normal, around the industry mean (2.788). P/E Ratio (-1.173) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PBYI | RNAC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 54 | 100 | |
SMR RATING 1..100 | 44 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 72 | |
P/E GROWTH RATING 1..100 | 2 | 25 | |
SEASONALITY SCORE 1..100 | 31 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RNAC's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for PBYI (85). This means that RNAC’s stock grew somewhat faster than PBYI’s over the last 12 months.
PBYI's Profit vs Risk Rating (54) in the Biotechnology industry is somewhat better than the same rating for RNAC (100). This means that PBYI’s stock grew somewhat faster than RNAC’s over the last 12 months.
PBYI's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for RNAC (100). This means that PBYI’s stock grew somewhat faster than RNAC’s over the last 12 months.
PBYI's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for RNAC (72). This means that PBYI’s stock grew somewhat faster than RNAC’s over the last 12 months.
PBYI's P/E Growth Rating (2) in the Biotechnology industry is in the same range as RNAC (25). This means that PBYI’s stock grew similarly to RNAC’s over the last 12 months.
| PBYI | RNAC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 84% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 78% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 78% |
| Advances ODDS (%) | 3 days ago 89% | 3 days ago 83% |
| Declines ODDS (%) | 5 days ago 79% | 5 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 83% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PBYI’s FA Score shows that 1 FA rating(s) are green while RNAC’s FA Score has 2 green FA rating(s).
- PBYI’s FA Score: 1 green, 4 red.
- RNAC’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PBYI’s TA Score shows that 4 TA indicator(s) are bullish while RNAC’s TA Score has 5 bullish TA indicator(s).
- PBYI’s TA Score: 4 bullish, 5 bearish.
- RNAC’s TA Score: 5 bullish, 4 bearish.
Price Growth
PBYI (@Biotechnology) experienced а -7.31% price change this week, while RNAC (@Biotechnology) price change was +0.44% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.71%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was -17.15%.
Reported Earning Dates
PBYI is expected to report earnings on Mar 04, 2027.
RNAC is expected to report earnings on Mar 17, 2027.
Industries' Descriptions
@Biotechnology (+4.71% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement